{"groups":[{"description":"Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 milligrams (mg)/kilogram (kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of every 3-week cycle (Q3W).","id":"FG000","title":"Mirvetuximab Soravtansine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"62"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other than specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"106"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"105"}],"type":"INV Efficacy Evaluable Population"},{"achievements":[{"groupId":"FG000","numSubjects":"38"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"68"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were enrolled at 39 sites in North America, Europe, and Asia Pacific."}